Treatment-emergent grade 3 to 5 adverse events in ≥10% of patients during any phase of therapy
| Adverse event . | Induction (N = 70), n (%) . | Consolidation (n = 59), n (%) . | Maintenance (n = 46), n (%) . |
|---|---|---|---|
| Febrile neutropenia | 29 (41) | 31 (53) | 2 (4) |
| Infection | 14 (20) | 14 (24) | 4 (9) |
| Hyperglycemia | 12 (17) | 5 (8) | 5 (11) |
| AST/ALT/GGT/ALP | 11 (16) | 6 (10) | 6 (13) |
| Headache | 10 (14) | 10 (17) | 7 (15) |
| Hypoxia | 10 (14) | 0 (0) | 1 (2) |
| DIC | 8 (11) | 1 (2) | 0 (0) |
| Dyspnea | 8 (11) | 4 (7) | 2 (4) |
| QTc prolonged | 8 (11) | 3 (5) | 0 (0) |
| Hypokalemia | 7 (10) | 4 (7) | 0 (0) |
| Fatigue | 4 (6) | 8 (14) | 4 (9) |
| Pain | 4 (6) | 8 (14) | 2 (4) |
| Nausea | 2 (3) | 7 (12) | 6 (13) |
| Hematologic | |||
| Neutrophils | NA | 9 (20) | |
| Hemoglobin | NA | 3 (7) | |
| Platelets | NA | 3 (7) | |
| Adverse event . | Induction (N = 70), n (%) . | Consolidation (n = 59), n (%) . | Maintenance (n = 46), n (%) . |
|---|---|---|---|
| Febrile neutropenia | 29 (41) | 31 (53) | 2 (4) |
| Infection | 14 (20) | 14 (24) | 4 (9) |
| Hyperglycemia | 12 (17) | 5 (8) | 5 (11) |
| AST/ALT/GGT/ALP | 11 (16) | 6 (10) | 6 (13) |
| Headache | 10 (14) | 10 (17) | 7 (15) |
| Hypoxia | 10 (14) | 0 (0) | 1 (2) |
| DIC | 8 (11) | 1 (2) | 0 (0) |
| Dyspnea | 8 (11) | 4 (7) | 2 (4) |
| QTc prolonged | 8 (11) | 3 (5) | 0 (0) |
| Hypokalemia | 7 (10) | 4 (7) | 0 (0) |
| Fatigue | 4 (6) | 8 (14) | 4 (9) |
| Pain | 4 (6) | 8 (14) | 2 (4) |
| Nausea | 2 (3) | 7 (12) | 6 (13) |
| Hematologic | |||
| Neutrophils | NA | 9 (20) | |
| Hemoglobin | NA | 3 (7) | |
| Platelets | NA | 3 (7) | |
ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; DIC, disseminated intravascular coagulation; GGT, γ-glutamyl transferase; NA, not applicable; QTc, QT interval corrected for heart rate.